DHE in the Pharmacotherapy of Migraine: Potential for a Larger Role

@article{Saper2006DHEIT,
  title={DHE in the Pharmacotherapy of Migraine: Potential for a Larger Role},
  author={Joel R. Saper and Stephen D. Silberstein and David W. Dodick and Alan M. Rapoport},
  journal={Headache: The Journal of Head and Face Pain},
  year={2006},
  volume={46}
}
Despite a large array of currently marketed, frequently effective drugs for the acute treatment of migraine headache, comprising various classes and formulations, predictably reliable treatment for most headache types is often lacking. Dihydroergotamine mesylate (DHE) is a comparatively safe and effective therapy for migraine headache that could potentially be used for a broader range of headache types than occurs at present. The features of DHE supporting this assertion include (1… Expand
Dihydroergotamine: role in the treatment of migraine
  • M. Schürks
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2009
TLDR
Evaluated methods suggest that dihydroergotamine is particularly useful in migraineurs not satisfactorily responding to analgesics, in those with long attacks or headache recurrence, and those at risk of medication-overuse headache. Expand
Dihydroergotamine Infusion Therapy
TLDR
Intravenous dihydroergotamine is a relatively underutilized medication with a plethora of supportive clinical evidence for its use in persons with numerous headache disorders, but it has an adverse effect profile that includes myocardial, cerebral, or peripheral limb ischemic or infarction. Expand
Outpatient treatment of migraine headache, can we use a dexamethasone containing regimen?
TLDR
In emergency department, intravenous dexamethasone and metoclopramide may be considered as an effective and available treatment with few side effects especially for patients with long-lasing and intractable migraine attacks; however, it must be used limitedly. Expand
Acute treatment of migraine headaches.
TLDR
Clinicians should utilize evidence-based acute migraine-specific therapy stressing the imperative acute treatment goal of early intervention, but not too often with the correct drug, formulation, and dose. Expand
New drugs for migraine
TLDR
In the future, development and enhancements of existing medicines must be accompanied by increased efforts to develop truly new migraine drugs based on knowledge of the pathophysiology if one wishes to reduce substantially the great burden migraine poses on patients and society. Expand
Treatment of migraine in the emergency department
TLDR
The best evidence regarding the acute treatment of migraine is reviewed, describing major advances and the conventional drugs that remain as effective treatments. Expand
MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine
TLDR
Both Phase II and III clinical trials support anti-migraine efficacy with superior tolerability withMAP0004 compared with intravenous DHE, and the future use of MAP0004 as a first-line acute migraine treatment is supported. Expand
Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study
TLDR
The data suggest that intravenous methylergonovine can be an effective and safe drug in the management of severe migraine attacks in the emergency room. Expand
Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review
  • P. Tfelt-Hansen
  • Medicine
  • Cephalalgia : an international journal of headache
  • 2013
TLDR
DHE has a slow dissociation from the receptor; and this basic attribute of the drug is the most likely cause of the general relatively slow anti-migraine effect of DHE. Expand
Perimenstrual headache: Treatment options
TLDR
The notion that MM is more severe, longer in duration, and more resistant to treatment than headaches occurring at other times during the menstrual cycle may apply more to women seeking treatment for their headaches than to migraineurs in the general population. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 61 REFERENCES
Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.
TLDR
Self-administration of dihydroergotamine resulted in significant increases in pain relief and functional ability and significant decreases in pain intensity and nausea compared with the placebo and the present results suggest that intranasal administration of diHydroergOTamine represents an important new therapeutic option for migraine sufferers. Expand
Acute Treatment of Migraine With Dihydroergotamine Nasal Spray
TLDR
Self-administration of dihydroergotamine resulted in significant increases in pain relief and functional ability and significant decreases in pain intensity and nausea compared with the placebo, and the present results suggest that intranasal administration of di dehydration represents an important new therapeutic option for migraine sufferers. Expand
Intranasal Medications for the Treatment of Migraine and Cluster Headache
TLDR
It is the opinion that nasal preparations increase therapeutic options and may result in faster response times and better efficacy than oral formulations and better patient satisfaction than injectable preparations. Expand
Rizatriptan Combined with Rofecoxib Vs. Rizatriptan for the Acute Treatment of Migraine: an Open Label Pilot Study
TLDR
It is demonstrated that combining a fast acting triptan such as rizatriptan with rofecoxib reduced headache recurrence rates, was well tolerated and may be more effective than the use of riz atriptan alone. Expand
Efficacy of oral naratriptan in the treatment of menstrually related migraine
TLDR
Naratriptan given orally at a dose of 2.5 mg is effective in the acute treatment of MRM as early as 2 h after treatment, and patient overall satisfaction is found. Expand
Drug-Induced Headache: Long-Term Follow-Up of Withdrawal Therapy and Persistence of Drug Misuse
TLDR
The data show a higher relapse rate than previously assumed and that certain substance groups bear aHigher relapse risk. Expand
Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
TLDR
Both DHE and ET are safe and effective when used in recommended doses, and nearly 50 years of clinical experience without major safety problems allows a high level of confidence in their clinical use. Expand
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine
TLDR
Frovatriptan 2.5 mg given prophylactically twice daily for 6 days was effective in reducing the incidence of menstrual associated migraine, but the benefit was modest and one-third of women selected for predictable cycles were inaccurate in their predictions, so treatment success in clinical practice may even be lower. Expand
Rizatriptan in the Treatment of Menstrual Migraine
TLDR
Rizatriptan is effective in the treatment of menstrually associated migraine attacks and was as effective in treating menstrual as well as nonmenstrual migraine. Expand
Defeating migraine pain with triptans: A race against the development of cutaneous allodynia
TLDR
The probability of consistent pain‐free outcome increases drastically if triptan therapy is vigilantly timed to precede any signs of cutaneous allodynia, a phenomenon that develops gradually during the course of the migraine attack. Expand
...
1
2
3
4
5
...